Form 4: Alnylam Director Colleen Reitan Receives Equity Grant
Statement of Changes in Beneficial Ownership
Director Colleen F. Reitan was granted 671 restricted stock units and 1,441 stock options as part of Alnylam Pharmaceuticals' incentive plan.
Summary
- Director Colleen F. Reitan acquired 671 restricted stock units (RSUs) on May 20, 2026.
- The director also received 1,441 stock options with an exercise price of $298.48.
- Both the RSUs and stock options vest in full on the earlier of the first anniversary of the grant date or the director's retirement/resignation (if within 90 days of the anniversary).
- Following these transactions, the director holds 1,446 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no material impact on the company's financial outlook.
Positives
- Equity-based compensation aligns the interests of the director with those of shareholders.
Negatives
- None identified.
Risks
- The value of the equity grants is subject to market volatility and the future performance of Alnylam Pharmaceuticals' stock price.
Future Outlook
The equity grants are subject to standard vesting schedules tied to continued service or retirement/resignation conditions.
Industry Context
StockSavvy.ai notes that standard equity grants to non-employee directors are a common practice in the biotechnology sector to ensure long-term alignment with corporate governance and shareholder value creation.
Comparison to Industry Standards
- The grant of RSUs and stock options to directors is consistent with standard compensation practices for mid-to-large cap pharmaceutical companies.
- Vesting schedules of one year are typical for annual director equity awards in the industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Grant | Grant of RSUs and stock options under the Second Amended and Restated 2018 Stock Incentive Plan. | 05/20/2026 | Standard compensation alignment. |
Stakeholder Impact
- Minimal impact on shareholders as these are standard director compensation awards.
Next Steps
- Vesting of equity grants on May 20, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/20/2026 | Date of the equity grant transaction. |
| 05/20/2027 | Vesting date for the stock options and RSUs. |
| 05/20/2036 | Expiration date for the stock options. |
Keywords
Alnylam Pharmaceuticals, ALNY, Form 4, Insider Trading, Director Compensation, Equity Incentive Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.